Cancer generally takes years to evolve, and early diagnosis can prevent life-threatening cancer. Establishing a link between precancerous states and cancer is essential for effective screening and prevention. Esophageal adenocarcinoma (EAC) is an increasingly prevalent, poor-outcome cancer, and its presumed precursor, Barrett’s esophagus (BE), characterized by intestinal metaplasia, is evident in only about half of cases. Here to test whether BE is a prerequisite to EAC, we integrated epidemiological and clinical characteristics in a prospective cohort of 3,100 patients with EAC for any evidence of BE (BE-positive and BE-negative) and compared genomic features using a subset of 710 patients with whole-genome sequencing and 87 patients (380 samples) with multiregional whole-exome sequencing. Demographic and genomic features typically associated with BE were observed across BE-positive and BE-negative EAC cases. Notably, molecular features consistent with early BE evolution were detected in both phenotypes. Advanced tumor stage was the only variable that corresponded with increased likelihood of BE-negative EAC, including in some patients with a previous BE diagnosis. Phylogenetic analyses revealed shared evolutionary trajectories, and spatial transcriptomic and proteomic analyses demonstrated intestinal metaplasia-associated lineage markers in both groups. These findings suggest a single pathway to EAC, with implications for early diagnosis and prevention strategies.
8 July 2025 in Foregut: The Journal of the American Foregut Society
Minimally invasive esophageal cellular collection devices such as the Capsule Sponge may offer the potential for targeted screening of high-risk patients. The capsule sponge has been shown to be a safe, accurate and effective means of detecting Barrett’s esophagus. Here, we explore two potential real-life scenarios that could occur in a future screening or case finding programme. Firstly, when the capsule sponge test result is positive but confirmatory endoscopy demonstrates <1cm of columnar epithelium and secondly when subsequent endoscopy identifies gastric intestinal neoplasia. We discuss the clinical implication of the result and suggest how these patients could potentially be followed up in the future.
Cancer generally takes years to evolve, and early diagnosis can prevent life-threatening cancer 1,2 . Symptomatic, advanced cancers often lack evidence of a precancer at diagnosis and yet, if the link between a precancerous state and cancer can be proven, the opportunity arises for screening and prevention. Oesophageal adenocarcinoma (EAC) is an increasingly prevalent, 3 poor outcome cancer and its presumed precursor, Barrett’s oesophagus (BE) is only evident in around half of cases 4,5 . To test the hypothesis that BE is not a pre-requisite to EAC we classified a prospective cohort of 3,100 EAC patients for any evidence of BE and compared the epidemiological, clinical and genomic characteristics. Our findings demonstrate that there are specific demographic and genomic features observed in BE that also correlate strongly with EAC, regardless of the presence of a BE phenotype. Further we found evidence for the earliest features of BE evolution in both BE-negative and BE-positive EAC phenotypes. Advanced tumour stage was the only variable that corresponded with increased likelihood of BE-negative EAC, including in some patients with a prior diagnosis of Barrett’s. The role of a single BE-mediated pathway to EAC has implications for early diagnosis strategies. We anticipate that our methodology combining large epidemiological and genomic datasets with respect to phenotype could help establish the significance of other precancer states.